Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Nature Biotechnology's academic spinouts of 2016

An Erratum to this article was published on 01 August 2017

This article has been updated

Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellular imaging.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Change history

  • 25 May 2017

    In the version of this article initially published, on p.326, column 3, Shawn Marcell was described as “an economist turned pathologist,” rather than “an economist and entrepreneur.” Four lines below, his name was misspelled as “Marcel.” On p.329, the thumbnail caption named Kuball CEO; he is CSO, as it says in the text. On p.330, column 3, David Pompliano was incorrectly said to be “a partner at Apple Tree Partners (New York).” On p.331, column 1, Exicure CEO Giljohann’s first name was given as John in the caption; it is David. In column 2, paragraph 1 (and also in column 3, paragraph 3), AuraSense should have been AuraSense Therapeutics; paragraph 2, line 1, “AuraSense described” should have been “the Mirkin group described”; paragraph 4, line 1, “Exicure has published” should have been “The Mirkin group has published”; last paragraph, “upfront payment and equity investment” should have been “upfront payment and potential equity investment.” In column 3, paragraph 1, “ectopic dermatitis” should have been “atopic dermatitis”; in paragraph 2, the last half of the last sentence, “to enter a phase 1 trial in combination with a checkpoint inhibitor to treat solid tumors in the first half of 2017” should have read “to enter a phase 1 safety study in healthy volunteers in the first half of 2017, and is expected to enter a trial in combination with a checkpoint inhibitor to treat solid tumors in the first half of 2018.” The errors have been corrected in the HTML and PDF versions of the article.

References

  1. Oldenborg, P.-A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051–2054 (2000).

    CAS  Article  Google Scholar 

  2. Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).

    CAS  Article  Google Scholar 

  3. Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286–299 (2009).

    CAS  Article  Google Scholar 

  4. Chao, M.P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94 (2010).

    CAS  Article  Google Scholar 

  5. Horrigan, S.K. Replication study: the CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. eLife 6, e18173 (2017).

    Article  Google Scholar 

  6. Willingham, S.B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109, 6662–6667 (2012).

    CAS  Article  Google Scholar 

  7. Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90 (2016).

    CAS  Article  Google Scholar 

  8. Palchaudhuri, R. et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat. Biotechnol. 34, 738–745 (2016).

    CAS  Article  Google Scholar 

  9. Hsiao, E.Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451–1463 (2013).

    CAS  Article  Google Scholar 

  10. Sampson, T.R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167, 1469–1480.e12 (2016).

    CAS  Article  Google Scholar 

  11. Lee, J.H. et al. Highly multiplexed subcellular RNA sequencing in situ. Science 343, 1360–1363 (2014).

    CAS  Article  Google Scholar 

  12. Munger, J.S. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).

    CAS  Article  Google Scholar 

  13. Horan, G.S. et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177, 56–65 (2008).

    CAS  Article  Google Scholar 

  14. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301–305 (2014).

    Article  Google Scholar 

  15. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301–305 (2014).

    Article  Google Scholar 

  16. Winter, G.E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).

    CAS  Article  Google Scholar 

  17. Dai, H., Wang, Y., Lu, X. & Han, W. Chimeric antigen receptors modified T-cells for cancer therapy. J. Natl. Cancer Inst. 108, djv439 (2016).

    Article  Google Scholar 

  18. Bonneville, M., O'Brien, R.L. & Born, W.K. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10, 467–478 (2010).

    CAS  Article  Google Scholar 

  19. Gentles, A.J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).

    CAS  Article  Google Scholar 

  20. Fournié, J.J. et al. What lessons can be learned from gδ T cell-based cancer immunotherapy trials? Cell. Mol. Immunol. 10, 35–41 (2013).

    Article  Google Scholar 

  21. Marcu-Malina, V. et al. Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive gdT-cell receptor. Blood 118, 50–59 (2011).

    CAS  Article  Google Scholar 

  22. Sebestyen, Z. et al. RhoB mediates phosphoantigen recognition by Vγ9Vδ2T cell receptor. Cell Rep. 15, 1973–1985 (2016).

    CAS  Article  Google Scholar 

  23. Choi, C.H., Hao, L., Narayan, S.P., Auyeung, E. & Mirkin, C.A. Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc. Natl. Acad. Sci. USA 110, 7625–7630 (2013).

    CAS  Article  Google Scholar 

  24. Radovic-Moreno, A.F. et al. Immunomodulatory spherical nucleic acids. Proc. Natl. Acad. Sci. USA 112, 3892–3897 (2015).

    CAS  Article  Google Scholar 

  25. Wang, J. & Quake, S.R. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc. Natl. Acad. Sci. USA 111, 13157–13162 (2014).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bouchie, A., DeFrancesco, L., Sheridan, C. et al. Nature Biotechnology's academic spinouts of 2016. Nat Biotechnol 35, 322–333 (2017). https://doi.org/10.1038/nbt.3847

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3847

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing